T cell-based immunotherapies, including CAR-T cell therapies, have significantly advanced treatment options for lymphomas such as diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL).

Roles of EZH2 in cancer. Genes & Diseases publishes rigorously peer-reviewed and high quality original articles and authoritative reviews that focus on the molecular bases of human diseases.

The critical role of EZH2, an essential epigenetic regulator, in cancer progression and treatment is underscored in this new review article published in Genes & Diseases. The study highlights the ...

Eisai has reached an agreement with Japan’s National Cancer Centre to run a trial of its EZH2 inhibitor Tazverik in young people with cancers who either have no drug treatment available or have ...

Using an unbiased approach, this important study discovered a role of Ezh2 in the differentiation of granule neuron precursors, the cell of origin for Shh group of medulloblastoma. Furthermore, the ...

Some epigenetic drugs designed to treat cancer have the potential to be used as broad-spectrum antivirals. HMT EZH2/1 inhibitors can prevent viral gene expression and reduce herpes simplex virus ...

In Five Cancer Types, Prevention and Screening Have ... Nov. 20, 2024 — An enzyme called EZH2 has an unexpected role in driving aggressive tumor growth in treatment-resistant prostate cancers ...

Lung cancer remains one of the leading causes of ... Emerging targets, including EZH2, BRD4, and NSD3, are under investigation to enhance the efficacy of current treatment regimens.

Overcoming clinical resistance to EZH2 inhibition using rational epigenetic combination therapy. Cancer Discovery, 2024. Yamada M, Keller R, Cameron D, Suzuki H, Sanghrajka R, Vaynshteyn J, Gerwin J, ...

TAZVERIK ® is a registered trademark of Epizyme Inc., an Ipsen company.